Zosano Pharma Corp

Zosano Pharma — Investor Presentation (January 2022)

44 slides from Zosano Pharma's investor presentation, Jan 31, 2022

  1. Slide 1: Corporate Presentation January 2022

    Copyright © 2022 Zosano Pharma Corporation Corporate Presentation January 2022 1 Exhibit 99.1

  2. Slide 2: Disclaimer

    Copyright © 2022 Zosano Pharma Corporation Disclaimer 2 This presentation contains forward-looking statements regarding the benefits and potential uses of Zosano’s transdermal microneedle system and product candidates, including M207, the resubmission strategy of the M207 New Drug Application, the p

  3. Slide 3: Zosano Pharma: Working to Transform How Drugs Are Delivered

    Copyright © 2022 Zosano Pharma Corporation Zosano Pharma: Working to Transform How Drugs Are Delivered 3 Significant Clinical Evidence Versatile Platform Differentiated Technology OUR MISSION Advancing Patient Care and Transforming Patient Lives Through Therapies Developed Utilizing Our Proprietary

  4. Slide 4: Executive Summary and Recent Developments

    Copyright © 2022 Zosano Pharma Corporation Executive Summary and Recent Developments 4 Transformative Delivery Platform Addressing Significant Unmet Needs in Migraine Platform Development Key Developments ▪ Migraine is Ranked Globally as the Seventh Most Disabling Disease1 ▪ Migraine Impacts approxi

  5. Slide 5: Zosano's Transdermal Drug Delivery

    Copyright © 2022 Zosano Pharma Corporation Zosano’s Transdermal Drug Delivery 5 Novel & Proprietary Transdermal patch with drug-coated microneedle array Designed to be Rapid & Consistent Designed for rapid and consistent absorption of drugs into capillary bed Designed to Minimize Application Site Se

  6. Slide 6: M207 Designed for Optimization of Zolmitriptan Delivery

    Copyright © 2022 Zosano Pharma Corporation M207 Designed for Optimization of Zolmitriptan Delivery 6

  7. Slide 7: Designed to Address Unmet Needs in Migraine

    Copyright © 2022 Zosano Pharma Corporation DESIGNED TO ADDRESS UNMET NEEDS IN MIGRAINE 7

  8. Slide 8: Migraine is Highly Prevalent, Debilitating and Costly

    Copyright © 2022 Zosano Pharma Corporation Migraine is Highly Prevalent, Debilitating and Costly 8 Prevalent1 ▪ 3rd Most Prevalent Disorder in the World ▪ Impacts ~25% of U.S. Households ▪ Occurs in 12% of U.S. Population ▪ 90% Unable to Function Normally ▪ 1.2 MM ER Visits per Year ▪ 25% of women e

  9. Slide 9: Patients Want Fast and Complete Pain Relief that Lasts

    Copyright © 2022 Zosano Pharma Corporation Patients Want Fast and Complete Pain Relief that Lasts 74% of Sufferers 38% of Sufferers 49% of Sufferers 65% of Sufferers Reported Inadequate Treatment Response Reported Rapid Headache Onset Reported Inadequate 2 Hour Pain Freedom Reported Recurrence of He

  10. Slide 10: Society Guidelines on Goals of Acute Treatment of Migraine

    Copyright © 2022 Zosano Pharma Corporation What Do Society Guidelines Tell Us About the Goals of Acute Treatment of Migraine? The 2018/2021 American Headache Society Position Statements On Integrating New Migraine Treatments Into Clinical Practice3,4 ▪ Rapid and consistent freedom from pain and asso

  11. Slide 11: Triptans Are and Will Likely Remain the Standard of Care

    Copyright © 2022 Zosano Pharma Corporation Triptans Are and Will Likely Remain the Standard of Care 11 1.Lipton et al. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache 2019;59:1310-1323. 2.GlaxoSmithKline. (2013). IMITREX (sumatriptan) Nasal Spray

  12. Slide 12: 1. Biohaven Holding Company Ltd. Nurtec® (Rimegepant) [package insert]. U.S. Food and Drug Administration

    Copyright © 2022 Zosano Pharma Corporation 1. Biohaven Holding Company Ltd. Nurtec® (Rimegepant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf. Revised 2/2020. Accessed August 31, 2021. 2 Allergan Pharmaceutic

  13. Slide 13: Stratified Treatment Plan Toolbox Approach

    Copyright © 2022 Zosano Pharma Corporation A Stratified Treatment Plan Incorporating a Toolbox Approach is Key to Optimizing Treatment of Acute Attacks “There are foreseeable scenarios in which a patient may have 2 different triptans, an NSAID, and a ditan or gepant in their tool kit”2 ▪ Migraine is

  14. Slide 14: M207 Clinical Results From Phase 2/3 ZOTRIP Study

    Copyright © 2022 Zosano Pharma Corporation M207 Clinical Results From Phase 2/3 ZOTRIP Study 15 Mins Results 23% of Patients Achieved Pain Relief Efficacy Results Activity 81% 42% Observed Peak Plasma Concentration Reported Pain Freedom at 2 Hours 78% Reported Pain Relief at 24 Hours Reported Pain R

  15. Slide 15: Results on Pain Freedom and Most Bothersome Symptom

    Copyright © 2022 Zosano Pharma Corporation 41.5% 68.3% 14.3% 42.9% 0% 20% 40% 60% 80% Pain Freedom MBS % S u b je c ts A c h ie v in g P a in F re e d o m o r F re e d o m fr o m M B S a t 2 H o u rs M207 3.8mg Placebo Clinically Significant Results on Pain Freedom and Most Bothersome Symptom (MBS)

  16. Slide 16: High Rates of Pain Freedom from 30 Minutes to 48 Hours

    Copyright © 2022 Zosano Pharma Corporation M207 Treatment Resulted in High Rates of Pain Freedom from 30 Minutes to 48 Hours 16 7.3% 17.1% 26.8% 41.5% 51.2% 54.9% 62.2% 69.5% 64.6% 0% 20% 40% 60% 30 minutes 45 minutes 1 hour 2 hour 3 hour 4 hour 12 hours 24 hours 48 hours % S u b je c ts A c h ie v

  17. Slide 17: Pain Relief 15 Minutes to 48 Hours

    Copyright © 2022 Zosano Pharma Corporation 23.2% 46.3% 56.1% 68.3% 80.5% 81.7% 82.9% 80.5% 78.0% 71.0% 0% 20% 40% 60% 80% 15 minutes 30 minutes 45 minutes 1 hour 2 hour 3 hour 4 hour 12 hours 24 hours 48 hours % S u b je c ts A c h ie v in g P a in R e li e f Pain Relief 15 Minutes to 48 Hours * **

  18. Slide 18: Sustained Pain Freedom Observed at 24 and 48 Hours

    Copyright © 2022 Zosano Pharma Corporation Sustained Pain Freedom Observed at 24 Hours and 48 Hours 41.5% 31.7% 26.8% 14.3% 10.4% 9.1% 0% 20% 40% 2 Hours 2-24 Hours* 2-48 Hours* % o f S u b je c ts w it h P F a t 2 H o u rs a n d S u s ta in e d P F a t 2 4 a n d 4 8 H o u rs Pain Freedom Over Time

  19. Slide 19: Positive Results in the Most Difficult Migraine Types

    Copyright © 2022 Zosano Pharma Corporation Positive Results Seen Even in the Most Difficult Migraine Types Migraine On Awakening 44% 69% Reported Pain Freedom at 2 Hours Migraine With Severe Pain Reported Pain Relief at 2 Hours 44% 33% Migraine With Nausea Reported Pain Freedom at 2 Hours Delayed Tr

  20. Slide 20: Long Term Safety Results Consistent with Placebo-Controlled Study

    Copyright © 2022 Zosano Pharma Corporation Long Term Safety Results Consistent with Placebo-Controlled Study Endpoint ZOTRIP Pivotal Study (Single Dose) Open-Label Long-Term Placebo (N = 77) M207 3.8 mg (N = 82) M207 3.8 mg (N = 5,617 attacks) Pain Freedom at 2 hours 14% 42% 44% Pain Relief at 2 hou

  21. Slide 21: M207 was Well Tolerated in the Long-Term Safety Study

    Copyright © 2022 Zosano Pharma Corporation M207 was Well Tolerated in the Long-Term Safety Study 21 ▪ Most Common Adverse Events were Application Site Redness/Swelling. ▪ 95% were Mild ▪ 80% Resolved Within 48 hours ▪ Less than 2% of Patients Reported Neurological Triptan-like Side Effects Such as D

  22. Slide 22: Favorable Migraine-ACT Responses From Long-Term Safety Trial

    Copyright © 2022 Zosano Pharma Corporation Favorable Migraine-ACT Responses From the Long-Term Safety Trial Proportion of Participants Who Answered “Yes” at 48 Weeks 22 Migraine-ACT questionnaire a standardized evaluation completed by patients to assess the effectiveness of a patient’s acute treatme

  23. Slide 23: Commercial Strategy

    Copyright © 2022 Zosano Pharma Corporation COMMERCIAL STRATEGY 23

  24. Slide 24: 8MM Migraine Patients Represent a Large, Focused Opportunity

    Copyright © 2022 Zosano Pharma Corporation 8MM Migraine Patients Represent a Large, Focused Opportunity 37 Million Suffer From Migraine • ~8 MM Patients Account for ~60% of All Monthly Headache Days Resulting in >150 Million Migraine-Days 29 million with 0 - 4 migraines/ month 5 – 9 10 - 14 15+ # Sp

  25. Slide 25: Patients Continue to Suffer Even with New Market Entrants

    Copyright © 2022 Zosano Pharma Corporation Patients Continue to Suffer Even with New Market Entrants 25 Neurologists Have a Difficult-To-Treat Population 67% Of Physicians’ Patients are on Preventive Therapy Experiencing > 4 Headaches Monthly 300+ Migraine Patients Treated Monthly (Avg.) 51% of Thes

  26. Slide 26: Neurologists Strongly Agree That...

    Copyright © 2022 Zosano Pharma Corporation Neurologists Strongly Agree That… 79% Still an UNMET NEED in the acute setting even in patients that respond to preventive therapy 70% Would offer a NON- ORAL triptan that offers fast and complete pain relief that is sustained and well tolerated 63% Using a

  27. Slide 27: Physician Market Research: Reaction to M207's Potential Product Profile

    Copyright © 2022 Zosano Pharma Corporation Physician Market Research: Strong Positive Reaction to M207’s Potential Product Profile Differentiated Potential Product Attributes Key Drivers for HCP Adoption ZS Associates May 2020 Market Research: Insights drawn from n=19 Neurologists, n=4 NP/PAs, n=11

  28. Slide 28: Payer Feedback on Market Access

    Copyright © 2022 Zosano Pharma Corporation Payer Feedback on Market Access for Product X, if Approved ▪ Recognition that Migraine Patients May Need Non-oral Treatment Options ▪ Speed of Onset and Sustained Response Noted as Positives ▪ Likely Formulary Placement Will be Tier 3 or Non-preferred After

  29. Slide 29: Strong Market Opportunity with a Compelling Value Proposition

    Copyright © 2022 Zosano Pharma Corporation Strong Market Opportunity with a Compelling Value Proposition Large and Concentrated Marketplace Differentiated Potential Clinical Profile ▪ Fast Onset of Action ▪ Significant Pain Freedom ▪ Lack of Recurrence ▪ Low Percentage of Triptan-like Side Effects ▪

  30. Slide 30: Development of M207

    Copyright © 2022 Zosano Pharma Corporation ▪ October: CRL from FDA ▪ December: Ended Enrollment in Phase 2/3 Cluster Study Development of M207 ▪ June: 1st Subject Enrolled In Pivotal Study ▪ November: Completion of Enrollment 2016 2017 20202019 30 2021 ▪ October: Publication of Pivotal Data in Cepha

  31. Slide 31: Cluster Headache

    Copyright © 2022 Zosano Pharma Corporation CLUSTER HEADACHE 31

  32. Slide 32: Significant Unmet Need in Cluster Headache

    Copyright © 2022 Zosano Pharma Corporation ▪ Cluster headaches, which occur in cyclical patterns or cluster periods, are one of the most painful types of headache ▪ 15%-22% Have Suicidal Ideations2 Significant Unmet Need in Cluster Headache 32 . Highly Disabling Chronic Neurological Condition1 Short

  33. Slide 33: Cluster Headache (C213) Clinical Trial Program Update

    Copyright © 2022 Zosano Pharma Corporation Cluster Headache (C213) Clinical Trial Program Update 33 Terminated Phase 2/3 Clinical Trial Design Cluster Patients: 120 Population: Chronic or episodic cluster headache sufferers Design: Each cluster headache sufferer will take a single dose to treat a qu

  34. Slide 34: Subjects Positive for Both Co-primary Endpoints

    Copyright © 2022 Zosano Pharma Corporation Percentage of Subjects who were Positive for Both Co-primary Endpoints 34 37.5% 44.4% 100.0% 0% 20% 40% 60% 80% 100% 15 MinuteP ro p o rt io n o f S u b je c ts R e p o rt in g P a in R e li e f a t 1 5 M in u te s Placebo C213 1.9 mg C213 3.8 mg N=5 ▪ A To

  35. Slide 35: Pipeline Expansion

    Copyright © 2022 Zosano Pharma Corporation PIPELINE EXPANSION 35

  36. Slide 36: Leveraging Platform & Clinical Validation for Pipeline Expansion

    Copyright © 2022 Zosano Pharma Corporation Leveraging Platform & Clinical Validation for Pipeline Expansion PRE-CLINICAL & CLINICAL PROOF-OF-CONCEPT STUDIES ▪ Initiated Three Collaborations in 2020 - Two Ongoing Feasibility Studies with Undisclosed Partners o Assessing feasibility for undisclosed mo

  37. Slide 37: Partnering Opportunity for Microneedle COVID-19 Vaccine

    Copyright © 2022 Zosano Pharma Corporation Partnering Opportunity for Development of Microneedle COVID-19 Vaccine ▪ Ongoing Work with COVID-19 Vaccine Developers ▪ Pursuing Non-dilutive Funding Opportunities for COVID -19 Programs Through Governmental Agencies Potential Benefits of Utilizing Zosano’

  38. Slide 38: Zosano Pharma Microneedle Array Drug Delivery System

    Copyright © 2022 Zosano Pharma Corporation Zosano Pharma Microneedle Array Drug Delivery System Ideal solution for delivery of peptides, proteins and hydrophilic drugs ▪ First generation transdermal patches limited to hydrophobic molecules ▪ Low bioburden manufacturing and terminal sterilization mit

  39. Slide 39: Dosage Flexibility Enabled by Formulation, Process and Design

    Copyright © 2022 Zosano Pharma Corporation Dosage Flexibility Enabled by Formulation, Process and Design 39 1. Formulation: Product formulation defines capability of coating on the microneedle substrate. Kept constant within a product family 2. Process: Multiple dips increase coated amount per micro

  40. Slide 40: Corporate Overview

    Copyright © 2022 Zosano Pharma Corporation CORPORATE OVERVIEW 40

  41. Slide 41: Select Financials (unaudited)

    Copyright © 2022 Zosano Pharma Corporation Select Financials (unaudited) ▪ Cash and cash equivalents as of September 30, 2021: $17.1m ▪ Total shares outstanding as of November 5, 2021: 118.3m ▪ Select financial information: 41 Three Months Ended September 30, Nine Months Ended September 30, 2021 202

  42. Slide 42: Experienced Management Team

    Copyright © 2022 Zosano Pharma Corporation Name Title Experience Steven Lo Chief Executive Officer Christine Matthews Chief Financial Officer Don Kellerman VP, Clinical Development & Medical Affairs Mahmoud Ameri VP, Research and Development Lu Liu VP, Technical Operations Greg Meyer VP, Quality Ass

  43. Slide 43: Board of Directors

    Copyright © 2022 Zosano Pharma Corporation Board of Directors 43 Name Title Experience Steven Elms Managing Partner, Aisling Capital Linda Grais, MD, JD Director, Zosano Pharma Kenneth R. Greathouse Director, Zosano Pharma Joseph Hagan President and Chief Executive Officer, Regulus Therapeutics Inc.

  44. Slide 44: P H A RM A

    P H A RM A

Zosano Pharma — Investor Presentation (January 2022) on 6ix